Friday November 27 2009 | Biotechnology feed | All feeds
|
|
GENOVAC GmbH
Download detailed PDF Members: The commitment and expertise of our people and our award winning technology has established GENOVAC as a world leader in the rapid generation of polyclonal and monoclonal antibodies through genetic immunization. Innovative proprietary methods enable us to produce highly specific, high-affinity antibodies based on the cDNA sequence alone. This will allow a rapid translation of the wealth of genomic information into extremely valuable tools especially suitable for the diagnosis and therapy of many diseases as well as for basic research. GENOVAC has adopted a dual strategy for the development of highest quality antibodies. In close collaboration with our customers we generate tailor-made antibodies to suit their specific requirements. In addition, based on the longstanding experience of our team, GENOVAC is developing its own portfolio of products.
This page has been viewed 368 times since April 2007, the link to the organisation's website has been followed 71 times Recent Search Terms used to find this page: genovac | genovac | GENOVAC GmbH | Genovac | genovac | . Search for more companies in Freiburg This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified. BioPortfolio search results for GENOVAC GmbH | |||||||||||||||||||||||||||||||||||||||||
|